| Literature DB >> 24135337 |
Pawel Mierzejewski1, Marcin Kolaczkowski, Natalia Nowak, Agnieszka Korkosz, Anna Scinska, Halina Sienkiewicz-Jarosz, Jerzy Samochowiec, Wojciech Kostowski, Przemyslaw Bienkowski.
Abstract
Zolpidem is a non-benzodiazepine hypnotic drug acting preferentially at α1-containing GABAA receptors expressed in various parts of the brain, including the basal ganglia. The aim of the present study was to provide preliminary characteristics of zolpidem-induced catalepsy in Wistar rats. Zolpidem (2.5-10.0mg/kg), but not diazepam and midazolam, produced dose-dependent cataleptic responses in the bar test, which were similar to those produced by a reference antipsychotic drug, haloperidol. Zolpidem-induced catalepsy was abolished by a benzodiazepine site antagonist, flumazenil (5.0mg/kg), D2/3 receptor agonist, quinpirole (1.0mg/kg), and a non-competitive NMDA receptor antagonist, MK-801 (0.1mg/kg), but not by a non-selective opioid receptor antagonist, naltrexone (3.0mg/kg). The present results indicate that systemic injections of zolpidem may produce short-lasting, neuroleptic-like catalepsy in the rat.Entities:
Keywords: Catalepsy; Flumazenil; Rat; The GABA(A) receptor; Zolpidem
Mesh:
Substances:
Year: 2013 PMID: 24135337 DOI: 10.1016/j.neulet.2013.10.011
Source DB: PubMed Journal: Neurosci Lett ISSN: 0304-3940 Impact factor: 3.046